IL-6R Inhibitors and Gastrointestinal Perforations: A Pharmacovigilance Study and a Predicting Nomogram
Shupeng Zou, Mengling Ouyang, Qian Cheng, Xuan Shi, Yazheng Zhao, Minghui Sun, Silvia Vidal, Ferenc Sipos · 2024
Read IL-6R Inhibitors and Gastrointestinal Perforations: A Pharmacovigilance Study and a Predicting Nomogram by Shupeng Zou, Mengling Ouyang, Qian Cheng, Xuan Shi, Yazheng Zhao, Minghui Sun, Silvia Vidal, Ferenc Sipos (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11673817.txt.
Description
Shupeng Zou and co-authors mined drug safety reports for a gut risk tied to inflammation drugs, in a 2024 study. The drugs block the IL-6 receptor and serve many diseases; reports of gut perforation under them keep rising. Drawing on the United States adverse event database, the team hunted for signals and built a risk prediction chart.
They found 994 perforation cases tied to two such drugs. Signals ran strong for both, and strongest for holes in the duodenum. Most events came within six months of starting, with a middle time near sixty days. Risk ran higher in women and in patients over forty. Their chart aims to flag fragile patients before harm.
Catalog record
| CREATOR | Shupeng Zou, Mengling Ouyang, Qian Cheng, Xuan Shi, Yazheng Zhao, Minghui Sun, Silvia Vidal, Ferenc Sipos |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 32 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |